Product information and disease descriptionPlace of product in therapyApproaches to treatment
Heterogeneity of treatment effect
17 evidence topics · 17 sources
HLA-A∗02:01 status: confirmed response in first-line and any-line participants of OptimUM-01, August 2023
HLA-A∗02:01 status: sponsor summary of first-line activity in the pooled OptimUM-01 population
Line of therapy and hepatic-only disease: OptimUM-01 per-protocol efficacy population, March 2023 data cutoff
MET pathway activity and response to darovasertib monotherapy
GNAQ and GNA11 mutations as the shared target population of PKC inhibition
Tebentafusp: overall survival in prespecified and exploratory subgroups with extended follow-up
Tebentafusp: baseline factors associated with longer overall survival and with survival of at least 5 years
“The baseline factors that were most associated with longer overall survival during treatment with tebentafusp included an ECOG performance-status score of 0, levels of LDH and alkaline phosphatase in the normal range, a largest metastatic lesion that was less than 8 cm in diameter, and a longer time since primary diagnosis (Table S5).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Tebentafusp: disease volume and line of therapy as modifiers of benefit in expert discussion
Tebentafusp: circulating tumor DNA reduction at week 9 and overall survival, 3-year analysis
“In an exploratory analysis, 202 of the 252 patients in the tebentafusp group had baseline and week 9 serum samples that were obtained during treatment and were available for ctDNA analysis; 123 of the patients with a sample (61%) had at least one detectable uveal mutation at baseline.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Likewise, patients who had clearance of ctDNA by week 9 had longer overall survival than those without clearance (median overall survival, 29.6 months vs. 10.2 months) (Fig. 3B).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall survival among the 99 patients who had a reduction of at least 50% in the ctDNA level was longer than that among the 24 patients who had a reduction of less than 50%, no change, or an increase in the ctDNA level (hazard ratio for death, 0.41; 95% CI, 0.25 to 0.67) (Fig. 3C).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Tebentafusp: circulating tumor DNA reduction by best response and baseline tumor burden, 5-year analysis
Tebentafusp: BAP1 loss in the control group
Tebentafusp: early rash as a predictor of overall survival
Immune checkpoint inhibitors: MBD4-deficient hypermutated tumors
“Here we present a metastatic uveal melanoma patient with an exceptional high sensitivity to a PD-1 inhibitor associated with outlier CpG>TpG mutation burden, MBD4 germline deleterious mutation, and somatic MBD4 inactivation in the tumor.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In our series of 42 metastatic UM patients treated with PD1inh, only one (UVM_IC) achieved a tumor response (details in Methods)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among the 12 patients who received ICIs, nine received pembrolizumab, two ipilimumab plus nivolumab followed by nivolumab, and one pembrolizumab plus lenvatinib within the frame of the PLUME phase 2 trial (NCT05282901).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The overall response rate was 50% (two complete, four partial) with a disease control rate of 83%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At 12 months, 73% of patients were progression free, and the estimated 2-year OS was 86%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Our findings support further evaluation of MBD4 mutation as a predictive biomarker and suggest that ICIs should be considered as a preferred first-line option in MBD4-mutated mUM.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Immune checkpoint inhibitors: low tumor mutational burden in GNAQ- or GNA11-mutant tumors
Immune checkpoint inhibitors: liver metastasis volume and extrahepatic-only disease
“Notably, the patients who benefited either had no liver metastases or small volume disease whereas rapidly progressing patients had bulky liver involvement.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“(A) PFS for patients with extrahepatic-only sites of metastases versus liver metastases was 12.0 months versus 5.5 months (P = .0918).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Twenty-seven evaluable patients had liver metastases, of whom five (19%) had a PR and three (11%) had stable disease for 6 months or longer.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with extrahepatic metastases only and treated with ipilimumab-nivolumab combination seem to have a better prognostic, the expected survival was 3.2 times higher than with any other systemic treatment (HR 0.28, 95% CI: 0.11–0.69).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Immune checkpoint inhibitors: lactate dehydrogenase level and outcomes
“Normal LDH was associated with improved OS (p=0.026)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, elevated LDH was not associated with significantly worse PFS.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote